In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 80 days of free consultation

 

Plaque characteristics, slow flow during percutaneous coronary intervention, and clinical outcomes of irregular protrusion by optical coherence tomography

Session Poster Session 6

Speaker Hideo Amano

Congress : ESC Congress 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Optical Coherence Tomography
  • Session type : Poster Session
  • FP Number : P5623

Authors : H Amano (Tokyo,JP), R Noike (Tokyo,JP), D Saito (Tokyo,JP), T Yabe (Tokyo,JP), I Watanabe (Tokyo,JP), M Koizumi (Tokyo,JP), R Okubo (Tokyo,JP), M Toda (Tokyo,JP), T Ikeda (Tokyo,JP)

Authors:
H Amano1 , R Noike1 , D Saito1 , T Yabe1 , I Watanabe1 , M Koizumi1 , R Okubo1 , M Toda1 , T Ikeda1 , 1Toho University Faculty of Medicine, Department of Cardiovascular Medicine - Tokyo - Japan ,

Citation:

Introduction: In pathological studies, penetration of the lipid core into the stent strut is associated with neointimal growth and stent thrombosis. Irregular protrusion on optical coherence tomography (OCT) is associated with clinical events and target lesion revascularization. However, there are few reports about the relationship among irregular protrusion, plaque characteristics, and slow flow during percutaneous coronary intervention. We investigated clinical and procedure characteristics, plaque characteristics, slow flow after stent implantation, and clinical outcomes with irregular protrusion by using OCT.
Methods: Eighty-four lesions in 76 patients undergoing OCT before percutaneous coronary intervention were evaluated. Irregular protrusion was defined as protrusion of material with an irregular surface into the lumen between stent struts with a maximum height of =100 µm. Major adverse clinical outcomes were defined as death, acute myocardial infarction, acute coronary syndrome, or target lesion revascularization.
Results: Lesions with irregular protrusion were found in 56% (47/84). Compared with lesions without irregular protrusion, those with irregular protrusion had significantly higher low-density lipoprotein cholesterol (LDL-C) levels (108 ± 31 mg/dL vs. 95 ± 25 mg/dL, P = 0.044); a tendency toward decreased use of statins (44% [19/43] vs. 67% [22/33], P = 0.065); significantly larger reference vessel diameter (3.12 ± 0.53 mm vs. 2.74 ± 0.63 mm, P = 0.004); significantly larger stent diameter (3.23 ± 0.43 mm vs. 3.00 ± 0.49 mm, P = 0.025); a tendency toward longer total stent length (29.3 ± 14.2 mm vs. 23.7 ± 11.4 mm, P = 0.056); significantly larger maximum balloon diameter (3.56 ± 0.55 mm vs. 3.22 ± 0.63 mm, P = 0.010); significantly higher incidence of slow flow after stent implantation (38% [18/47] vs. 11% [4/37], P = 0.006); significantly higher ?TIMI flow from pre-stenting to post-stenting (0.4 ± 0.6 vs. 0.1 ± 0.3, P = 0.009); significantly higher incidence of lipid-rich plaque (70% [33/47] vs. 35% [13/37], P = 0.002); thin-cap fibroatheromas (TCFAs: 49% [23/47] vs. 5% [2/37], P <0.001); plaque rupture (40% [19/47] vs. 16% [6/37], P = 0.018); macrophage accumulation (51% [24/47] vs. 24% [9/37], P = 0.015); internal running vasa vasorum (51% [24/47] vs. 11% [4/37], P <0.001); thrombus (32% [15/47] vs. 3% [1/37], P < 0.001); and a tendency higher incidence of one-year adverse clinical outcomes (12% [5/43] vs. 0% [0/33], P = 0.075: log rank). The multivariable analysis showed that TCFA was an independent predictor of irregular protrusion (odds ratio 9.00, 95% CI 1.32-61.36, P = 0.025).
Conclusions: Irregular protrusion on OCT was associated with high plaque vulnerability, higher LDL-C, less frequent use of statin, larger vessel diameter, longer total stent length, slow flow after stent implantation, and one-year adverse clinical outcomes.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are